Do not invest more money than you can afford to lose.
96
Normal
0false
false
falseEN-US
JA
X-NONE/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Calibri;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;}Doctors have found a new combination of injectable HIV drugs that could replace the daily oral treatments a few HIV-positive patients now take to suppress the virus.
HIV patients typically take a combination of three medicines every day, often in combination pills.
A single injection to a patient once every eight weeks has a higher viral suppression than patients on tablets, revealed the trial result.
Meanwhile, the suppression rate was 95 per cent for those receiving treatment every eight weeks. Rilpivirine has been Johnson & Johnson’s pill treatment for HIV since 2011. HIV also continues to be one of the world’s fatal viruses that have no cure.
However, not adhering to that strict schedule can result in the HIV virus coming back and growing resistant to the treatment, as often happens with patients struggling with other problems in their lives, Kuritzkes said.
Dr. John C Pottage of ViiV Healthcare said: “ViiV Healthcare is committed to identifying new therapeutic options for physicians and people living with HIV”.
Preliminary testing of two long-acting injectable drugs has indicated that it could be possible to keep HIV at bay forever with injections every month or two.
These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs).
According to the companies, nearly 75 million people have been infected with the HIV virus since the beginning of the AIDS epidemic.
Now for the caveats: There may still be a fair amount of progress to be made before this treatment approach becomes as popular as one-to-three pill regimens currently used to treat HIV. They will no longer go through the traditional 3-pill daily. He believes the combination could be on the market by 2020.
